Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Branislav Kovacech

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Neuro-Degenerative Diseases|February 18, 2010
Transition of tau protein from disordered to misordered in Alzheimer's diseaseBranislav Kovacech, Rostislav Skrabana, Michal Novak
Cellular and Molecular Neurobiology|February 20, 2009
New age of neuroproteomics in Alzheimer's disease researchBranislav Kovacech, Norbert Zilka, Michal Novak
Biochemical Society Transactions|July 24, 2012
The self-perpetuating tau truncation circleNorbert Zilka, Branislav Kovacech, Peter Barath, et al.
Alzheimer'S Research & Therapy|December 6, 2014
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease modelEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications|October 3, 2012
Crystallization and preliminary X-ray diffraction analysis of tau protein microtubule-binding motifs in complex with Tau5 and DC25 antibody Fab fragmentsOndrej Cehlar, Rostislav Skrabana, Andrej Kovac, et al.
Alzheimer'S Research & Therapy|December 6, 2014
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's diseaseEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
BMC Chemistry|August 7, 2019
Determination of immunogenic proteins in biopharmaceuticals by UHPLC-MS amino acid analysisJuraj Piestansky, Jaroslav Galba, Dominika Olesova, et al.
Acta Neuropathologica|April 10, 2010
CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathyNorbert Zilka, Miroslava Korenova, Branislav Kovacech, et al.
Journal of Neuroinflammation|October 13, 2010
Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's diseaseZuzana Stozicka, Norbert Zilka, Petr Novak, et al.
Neuro-Degenerative Diseases|March 22, 2012
Immunomodulation of memory-impairing protein tau in Alzheimer's diseaseNorbert Zilka, Zuzana Stozicka, Martin Cente, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Neuro-Degenerative Diseases|February 18, 2010
Transition of tau protein from disordered to misordered in Alzheimer's diseaseBranislav Kovacech, Rostislav Skrabana, Michal Novak
Cellular and Molecular Neurobiology|February 20, 2009
New age of neuroproteomics in Alzheimer's disease researchBranislav Kovacech, Norbert Zilka, Michal Novak
Biochemical Society Transactions|July 24, 2012
The self-perpetuating tau truncation circleNorbert Zilka, Branislav Kovacech, Peter Barath, et al.
Alzheimer'S Research & Therapy|December 6, 2014
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease modelEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications|October 3, 2012
Crystallization and preliminary X-ray diffraction analysis of tau protein microtubule-binding motifs in complex with Tau5 and DC25 antibody Fab fragmentsOndrej Cehlar, Rostislav Skrabana, Andrej Kovac, et al.
Alzheimer'S Research & Therapy|December 6, 2014
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's diseaseEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
BMC Chemistry|August 7, 2019
Determination of immunogenic proteins in biopharmaceuticals by UHPLC-MS amino acid analysisJuraj Piestansky, Jaroslav Galba, Dominika Olesova, et al.
Acta Neuropathologica|April 10, 2010
CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathyNorbert Zilka, Miroslava Korenova, Branislav Kovacech, et al.
Journal of Neuroinflammation|October 13, 2010
Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's diseaseZuzana Stozicka, Norbert Zilka, Petr Novak, et al.
Neuro-Degenerative Diseases|March 22, 2012
Immunomodulation of memory-impairing protein tau in Alzheimer's diseaseNorbert Zilka, Zuzana Stozicka, Martin Cente, et al.
Pageof 4